Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

Allergies are among the most common health issues affecting people worldwide, often leading to symptoms such as sneezing, itching, rashes, and breathing difficulties. At the core of most allergic ...